Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Orsini Now Distributing CASGEVY® (exagamglogene autotemcel), a Gene-Editing Therapy
Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene ...
The First Crispr Treatment Is Making Its Way to Patients
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...
The Pharma Letter1d
M&A activity – CRISPR fuelling investor interest in gene editing
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new ...
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
FiercePharma4d
Swiss CDMO Lonza to double its ADC prowess by adding 2 suites, 200 jobs at its Visp site
Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...
3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029
Detailed price information for Archer Aviation Inc (ACHR-N) from The Globe and Mail including charting and trades.
MaxCyte’s Strong Performance and Growth Potential Justifies Buy Rating by Mark Massaro
BTIG analyst Mark Massaro reiterated a Buy rating on MaxCyte (MXCT – Research Report) yesterday and set a price target of $8.00. Mark ...
News Medical2d
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics
MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...
Business Insider4d
Positive Outlook on Crispr Therapeutics AG Driven by Strong Pricing and Strategic Partnerships
Salim Syed’s rating is based on a combination of encouraging developments surrounding Crispr Therapeutics AG. Firstly, the pricing of Casgevy in Saudi Arabia appears to be around $2 million per ...